Clinical Trials Logo
  1. Home
  2. Generalized Myasthenia Gravis
  3. NCT03770403

A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. — ADAPT+  

Generalized Myasthenia Gravis Clinical Trial

Official title:
A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients With Myasthenia Gravis Having Generalized Muscle Weakness

Clinical Trial Summary

This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG. Patients who have completed at least 1 cycle of treatment and at least 1 year of trial ARGX-113-1705 and have started Part B are eligible to enroll in the open-label trial ARGX-113-2002 to receive efgartigimod by SC administration.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03770403
Study type Interventional
Source argenx
Contact
Status Completed
Phase Phase 3
Start date March 1, 2019
Completion date June 30, 2022
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05514873 - An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors Phase 3
Completed NCT04124965 - A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Phase 3
Recruiting NCT04833894 - Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis Phase 2/Phase 3
Recruiting NCT04963270 - A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis Phase 3
Active, not recruiting NCT02950155 - A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis Phase 3
Completed NCT03315130 - Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis Phase 2
Recruiting NCT05556096 - Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis Phase 3
Not yet recruiting NCT06149559 - A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis Phase 2/Phase 3
Completed NCT03920293 - Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis Phase 3
Not yet recruiting NCT06193889 - A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis Phase 2
Completed NCT03971422 - A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis Phase 3
Recruiting NCT05403541 - Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis Phase 3
Recruiting NCT05644561 - Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) Phase 3
Completed NCT00515450 - Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis Phase 3
Recruiting NCT06064695 - Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis N/A
Withdrawn NCT04982289 - Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis Phase 2
Completed NCT04735432 - Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis Phase 3
Completed NCT04650854 - A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis Phase 3
Active, not recruiting NCT05218096 - Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis Phase 2
Active, not recruiting NCT04225871 - Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis Phase 3